EE04589B1 - Vähivastaste ühendite valmistamise protsessid ja vaheühendid - Google Patents

Vähivastaste ühendite valmistamise protsessid ja vaheühendid

Info

Publication number
EE04589B1
EE04589B1 EEP200000255A EEP200000255A EE04589B1 EE 04589 B1 EE04589 B1 EE 04589B1 EE P200000255 A EEP200000255 A EE P200000255A EE P200000255 A EEP200000255 A EE P200000255A EE 04589 B1 EE04589 B1 EE 04589B1
Authority
EE
Estonia
Prior art keywords
intermediates
processes
preparation
anticancer compounds
anticancer
Prior art date
Application number
EEP200000255A
Other languages
English (en)
Estonian (et)
Inventor
Shelton Lehner Richard
Norris Timothy
Paul Santafianos Dinos
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200000255A publication Critical patent/EE200000255A/xx
Publication of EE04589B1 publication Critical patent/EE04589B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Metallurgy (AREA)
  • Mechanical Engineering (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200000255A 1999-03-31 2000-03-30 Vähivastaste ühendite valmistamise protsessid ja vaheühendid EE04589B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (2)

Publication Number Publication Date
EE200000255A EE200000255A (et) 2000-12-15
EE04589B1 true EE04589B1 (et) 2006-02-15

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000255A EE04589B1 (et) 1999-03-31 2000-03-30 Vähivastaste ühendite valmistamise protsessid ja vaheühendid

Country Status (49)

Country Link
US (1) US6476040B1 (sr)
EP (1) EP1044969B1 (sr)
JP (2) JP3420549B2 (sr)
KR (2) KR100430210B1 (sr)
CN (2) CN100351242C (sr)
AP (2) AP1265A (sr)
AR (1) AR018705A1 (sr)
AT (1) ATE348098T1 (sr)
AU (2) AU781402B2 (sr)
BG (1) BG65194B1 (sr)
BR (1) BRPI0001486B8 (sr)
CA (2) CA2302965C (sr)
CO (1) CO5160273A1 (sr)
CR (1) CR6165A (sr)
CZ (1) CZ299426B6 (sr)
DE (1) DE60032275T2 (sr)
DK (1) DK1044969T3 (sr)
DZ (1) DZ3030A1 (sr)
EA (3) EA005561B1 (sr)
EE (1) EE04589B1 (sr)
EG (1) EG22506A (sr)
ES (1) ES2278578T3 (sr)
GE (1) GEP20022653B (sr)
GT (1) GT200000037A (sr)
HR (1) HRP20000182B1 (sr)
HU (1) HU227698B1 (sr)
ID (1) ID25427A (sr)
IL (2) IL168036A (sr)
IS (1) IS2468B (sr)
MA (1) MA25087A1 (sr)
MY (1) MY136270A (sr)
NO (2) NO321952B1 (sr)
NZ (2) NZ503683A (sr)
OA (1) OA11335A (sr)
PA (1) PA8491901A1 (sr)
PE (1) PE20001599A1 (sr)
PL (1) PL339330A1 (sr)
PT (1) PT1044969E (sr)
RS (1) RS49836B (sr)
SG (2) SG121687A1 (sr)
SK (1) SK287339B6 (sr)
SV (1) SV2002000047A (sr)
TN (1) TNSN00064A1 (sr)
TR (1) TR200000837A2 (sr)
TW (1) TW553939B (sr)
UA (2) UA70928C2 (sr)
UY (1) UY26086A1 (sr)
YU (1) YU13200A (sr)
ZA (1) ZA200001586B (sr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
HRP20110958T1 (hr) * 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
PL1859793T3 (pl) * 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
KR101353763B1 (ko) 2005-11-07 2014-01-21 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CN104706637A (zh) * 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
EP2054393A1 (en) 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
EP2116246A1 (en) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
ES2573931T3 (es) * 2007-02-21 2016-06-13 Natco Pharma Limited Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
KR101441930B1 (ko) 2007-04-04 2014-09-19 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
US8389531B2 (en) 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
WO2009025875A1 (en) * 2007-08-23 2009-02-26 Plus Chemicals Sa Stable formulations of crystalline erlotinib hcl
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009096377A1 (ja) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. 血管阻害物質とタキサンとの併用
WO2009121042A1 (en) * 2008-03-28 2009-10-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
US20100004449A1 (en) * 2008-07-07 2010-01-07 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
WO2011058525A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
AU2011298167B2 (en) 2010-07-23 2015-11-26 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
ATE446955T1 (de) * 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
NZ508154A (en) 1998-04-29 2003-07-25 Osi Pharm Inc N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Also Published As

Publication number Publication date
UA70928C2 (uk) 2004-11-15
JP4074509B2 (ja) 2008-04-09
CO5160273A1 (es) 2002-05-30
HU227698B1 (en) 2011-12-28
IS2468B (is) 2008-12-15
EG22506A (en) 2003-03-31
CN100351242C (zh) 2007-11-28
HRP20000182A2 (en) 2001-04-30
MY136270A (en) 2008-09-30
BG65194B1 (bg) 2007-06-29
KR20020084903A (ko) 2002-11-13
PA8491901A1 (es) 2001-12-14
ES2278578T3 (es) 2007-08-16
EA200000274A3 (ru) 2003-02-27
BG104278A (en) 2001-08-31
SK4442000A3 (en) 2000-10-09
EP1044969A3 (en) 2000-11-29
PT1044969E (pt) 2007-05-31
RS49836B (sr) 2008-08-07
HUP0001353A2 (hu) 2001-05-28
JP2000290262A (ja) 2000-10-17
ID25427A (id) 2000-10-05
EE200000255A (et) 2000-12-15
AU2005201494B2 (en) 2008-02-07
SV2002000047A (es) 2002-01-23
NO20001648L (no) 2000-10-02
DZ3030A1 (fr) 2004-03-27
NZ512818A (en) 2003-01-31
US6476040B1 (en) 2002-11-05
CR6165A (es) 2008-10-10
KR20010014658A (ko) 2001-02-26
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
NO20054715L (no) 2000-10-02
GEP20022653B (en) 2002-03-25
SK287339B6 (sk) 2010-07-07
DE60032275D1 (de) 2007-01-25
EA004654B1 (ru) 2004-06-24
CN1215061C (zh) 2005-08-17
AP1265A (en) 2004-03-26
CN1276370A (zh) 2000-12-13
ATE348098T1 (de) 2007-01-15
OA11335A (en) 2003-12-10
IL135245A0 (en) 2001-05-20
UY26086A1 (es) 2000-10-31
YU13200A (sh) 2002-10-18
HUP0001353A3 (en) 2002-01-28
SG115536A1 (en) 2005-10-28
NO321952B1 (no) 2006-07-24
AU2005201494A1 (en) 2005-05-05
EA200201244A1 (ru) 2003-04-24
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
JP3420549B2 (ja) 2003-06-23
NZ503683A (en) 2001-09-28
BR0001486A (pt) 2001-05-02
CA2427221A1 (en) 2000-09-30
EP1044969B1 (en) 2006-12-13
BRPI0001486B1 (pt) 2019-01-29
KR100430210B1 (ko) 2004-05-03
EA200000274A2 (ru) 2000-10-30
TW553939B (en) 2003-09-21
AR018705A1 (es) 2001-11-28
KR100430209B1 (ko) 2004-05-03
NO20001648D0 (no) 2000-03-30
EA200201245A1 (ru) 2003-04-24
AP1655A (en) 2006-09-01
PL339330A1 (en) 2000-10-09
HK1029790A1 (en) 2001-04-12
PE20001599A1 (es) 2001-01-18
SG121687A1 (en) 2006-05-26
GT200000037A (es) 2001-09-21
CA2427221C (en) 2008-09-16
CN1699350A (zh) 2005-11-23
HU0001353D0 (en) 2000-06-28
JP2003176274A (ja) 2003-06-24
CA2302965A1 (en) 2000-09-30
DE60032275T2 (de) 2007-07-12
CZ299426B6 (cs) 2008-07-23
DK1044969T3 (da) 2007-04-23
AU781402B2 (en) 2005-05-19
CZ20001155A3 (cs) 2001-03-14
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
TR200000837A2 (tr) 2000-11-21
UA80955C2 (en) 2007-11-26
EP1044969A2 (en) 2000-10-18
ZA200001586B (en) 2001-10-01
IS5411A (is) 2000-10-02
BRPI0001486B8 (pt) 2021-05-25
CA2302965C (en) 2004-02-17
EA005892B1 (ru) 2005-06-30
MA25087A1 (fr) 2000-10-01
EA005561B1 (ru) 2005-04-28

Similar Documents

Publication Publication Date Title
EE200000255A (et) Vähivastaste ühendite valmistamise protsess ja vaheühendid
NO20015017D0 (no) Fremgangsmåte for fremstilling av citalopram
NO20010318L (no) Fremgangsmåte for fremstilling av Citalopram
NO20010319D0 (no) Fremgangsmåte for fremstilling av Citalopram
FI20000564A0 (fi) Menetelmä nanolaminaattien valmistamiseksi
PT1210113E (pt) Composicoes de vacinas de combinacao
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
EE04418B1 (et) Moksifloksatsiini farmatseutiline preparaat
EE200100536A (et) Amiini-plaatina komplekside valmistamismeetod
FI20011622A0 (fi) Menetelmä sitalopraamin valmistamiseksi
NO20013818L (no) Mikrobiell fremgangsmåte for fremstilling av pravastatin
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
NO20003454L (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
NO996432D0 (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
EE200000537A (et) Pürasolo[4,3-d]pürimidiin-7-oon-3-püridüülsulfonüülühendite ja nende vaheühendite valmistamise protsess
PT1175417E (pt) Compostos substituidos de benzolactamas
ITMI992048A0 (it) Procedimento stereoselettivo per la preparazione di endo-3-amminoazabi cicloalcani
DK1177165T3 (da) Fremgangsmåde til fremstilling af pesticidmellemprodukter
NO20022956D0 (no) Fremgangsmåte for fremstilling av nitroguanidin
NO20000805D0 (no) Fremgangsmåte for fremstilling av organiske azider
EE200100333A (et) Meetod 2-halo-3-nitro-4-aminopüridiini valmistamiseks ja selleks vajalike vaheühendite saamine
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110330